SCHEMBL2423486

SCHEMBL2423486

CC(C)[C@@H](C)Nc1cc(C(=O)O)c(Br)cc1C(N)=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
CA3 P07451 2/20 0.41
CA6 P23280 2/20 0.41
CA7 P43166 2/20 0.41
CA5B Q9Y2D0 2/20 0.41
CA12 O43570 1/20 0.41
CA4 P22748 1/20 0.41
CA5A P35218 1/20 0.41
CA9 Q16790 1/20 0.41
CA13 Q8N1Q1 1/20 0.41
CA14 Q9ULX7 1/20 0.41
LCK P06239 1/20 0.38
FYN P06241 1/20 0.38
HCAR3 P49019 2/20 0.38
HSD17B10 Q99714 2/20 0.36
TSHR P16473 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
ALDH1A1 P00352 2/20 0.33
KDM4E B2RXH2 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2425735 1.00 CA1 (0.41) CA1CA2CA3CA6CA7
SCHEMBL13450924 1.00 CA1 (0.41) CA1CA2CA3CA6CA7
SCHEMBL2426128 0.91 CA1 (0.42) CA1CA2CA3CA6CA7
SCHEMBL2427845 0.84 TSHR (0.41) CA1CA2CA3CA6CA7
SCHEMBL2424072 0.84 HCAR3 (0.42) HCAR3HSD17B10ALDH1A1KDM4EGLA
SCHEMBL2424070 0.84 HCAR3 (0.42) HCAR3HSD17B10ALDH1A1KDM4EGLA
SCHEMBL2425097 0.81 TSHR (0.41) CA1CA2CA3CA6CA7
SCHEMBL2428525 0.78 TSHR (0.46) CA1CA2CA3CA6CA7
SCHEMBL2429983 0.76 CA12 (0.42) CA1CA2CA3CA6CA7
SCHEMBL11781857 0.75 CA12 (0.53) CA1CA2CA3CA6CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8012956-B2 Tropane compounds EXELIXIS, INC. (US) 2011-09-06 US disclosed
US-8012956-B2 Tropane compounds EXELIXIS, INC. (US) 2011-09-06 US disclosed
US-8012956-B2 Tropane compounds EXELIXIS, INC. (US) 2011-09-06 US disclosed
EP-2074120-B1 TROPANE COMPOUNDS EXELIXIS INC (US) 2010-03-03 EP disclosed
US-20090163471-A1 Tropane compounds EXELIXIS, INC. 2009-06-25 US disclosed
US-20090163471-A1 Tropane compounds EXELIXIS, INC. 2009-06-25 US disclosed
US-20090163471-A1 Tropane compounds EXELIXIS, INC. 2009-06-25 US disclosed
WO-2009055077-A1 TROPANE COMPOUNDS EXELIXIS, INC. (US) 2009-04-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163471-A1 Tropane compounds ADRA1B, ADRA2B, ADRB2 CA1 3528/4885CA2 2509/4885CA3 4335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.